Resveratrol prevents renal lipotoxicity in high-fat diet-treated mouse model through regulating PPAR-α pathway

Molecular and Cellular Biochemistry

Volumn 411, Issue 1-2, 2016, Pages 143-150

  Zhou, Yan ^a   Lin, Suxian ^b   Zhang, Lihe ^c   Li, Yongji ^a  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^b WENZHOU PEOPLE'S HOSPITAL   (China)

^c WENZHOU CENTRAL HOSPITAL   (China)

Author keywords

High fat diet; Nephropathy; PPAR ; Resveratrol

Indexed keywords

4 HYDROXYNONENAL; CARNITINE PALMITOYLTRANSFERASE; COLLAGEN; GLUCOSE; GLYCOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; MEDIUM CHAIN ACYL COENZYME A DEHYDROGENASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; RESVERATROL; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TUMOR NECROSIS FACTOR ALPHA; UREA; STILBENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; GENE EXPRESSION; GLOMERULAR STRUCTURE; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KIDNEY DYSFUNCTION; KIDNEY INJURY; KIDNEY PARENCHYMA; LIPID DIET; LIPID STORAGE; LIPOTOXICITY; MALE; MICROALBUMINURIA; MOUSE; NONHUMAN; OBESITY; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RENAL LIPOTOXICITY; RENAL PROTECTION; SIGNAL TRANSDUCTION; UREA NITROGEN BLOOD LEVEL; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; DISEASE MODEL; KIDNEY; METABOLISM; PATHOLOGY;

ANIMALS; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; INFLAMMATION; KIDNEY; MALE; MICE; MICE, INBRED C57BL; OXIDATIVE STRESS; PPAR ALPHA; SIGNAL TRANSDUCTION; STILBENES;

EID: 84957433469     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-015-2576-y     Document Type: Article

References (36)

1. Liu ZH (2013) Nephrology in china. Nat Rev Nephrol 9:523–528. doi:10.1038/nrneph.2013.146
2. Ortiz A, Covic A, Fliser D, Fouque D, Goldsmith D, Kanbay M, Mallamaci F, Massy ZA, Rossignol P, Vanholder R, Wiecek A, Zoccali C (2014) London GM and Board of the E-mWGoERAE, Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet 383:1831–1843. doi:10.1016/S0140-6736(14)60384-6
3. de Vries AP, Ruggenenti P, Ruan XZ, Praga M, Cruzado JM, Bajema IM, D’Agati VD, Lamb HJ, Pongrac Barlovic D, Hojs R, Abbate M, Rodriquez R, Mogensen CE, Porrini E, Diabesity E-EWG (2014) Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease. Lancet Diabetes Endocrinol 2:417–426. doi:10.1016/S2213-8587(14)70065-8
4. Martinez-Rubio L, Morais S, Evensen O, Wadsworth S, Vecino JG, Ruohonen K, Bell JG, Tocher DR (2013) Effect of functional feeds on fatty acid and eicosanoid metabolism in liver and head kidney of Atlantic salmon (Salmo salar L.) with experimentally induced heart and skeletal muscle inflammation. Fish Shellfish Immunol 34:1533–1545. doi:10.1016/j.fsi.2013.03.363
5. Otten W, Wirth C, Iaizzo PA, Eichinger HM (1993) A high omega 3 fatty acid diet alters fatty acid composition of heart, liver, kidney, adipose tissue and skeletal muscle in swine. Ann Nutr Metab 37:134–141
6. Bell AW (1979) Lipid metabolism in liver and selected tissues and in the whole body of ruminant animals. Prog Lipid Res 18:117–164
7. Chanarin I, Patel A, Slavin G, Wills EJ, Andrews TM, Stewart G (1975) Neutral-lipid storage disease: a new disorder of lipid metabolism. Br Med J 1:553–555
8. Tanaka Y, Kume S, Araki S, Isshiki K, Chin-Kanasaki M, Sakaguchi M, Sugimoto T, Koya D, Haneda M, Kashiwagi A, Maegawa H, Uzu T (2011) Fenofibrate, a PPARalpha agonist, has renoprotective effects in mice by enhancing renal lipolysis. Kidney Int 79:871–882. doi:10.1038/ki.2010.530
9. Kim HJ, Sato T, Rodriguez-Iturbe B, Vaziri ND (2011) Role of intrarenal angiotensin system activation, oxidative stress, inflammation, and impaired nuclear factor-erythroid-2-related factor 2 activity in the progression of focal glomerulosclerosis. J Pharmacol Exp Ther 337:583–590. doi:10.1124/jpet.110.175828
10. Tonolo G, Cherchi S (2014) Tubulointerstitial disease in diabetic nephropathy. Int J Nephrol Renovasc Dis 7:107–115. doi:10.2147/IJNRD.S37883
11. Weinberg JM (2006) Lipotoxicity. Kidney Int 70:1560–1566. doi:10.1038/sj.ki.5001834
12. Park CW, Zhang Y, Zhang X, Wu J, Chen L, Cha DR, Su D, Hwang MT, Fan X, Davis L, Striker G, Zheng F, Breyer M, Guan Y (2006) PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney Int 69:1511–1517. doi:10.1038/sj.ki.5000209
13. Feng YH, Zou JP, Li XY (2002) Effects of resveratrol and ethanol on production of pro-inflammatory factors from endotoxin activated murine macrophages. Acta Pharmacol Sin 23:1002–1006
14. Hamza SM, Dyck JR (2014) Systemic and renal oxidative stress in the pathogenesis of hypertension: modulation of long-term control of arterial blood pressure by resveratrol. Front Physiol 5:292. doi:10.3389/fphys.2014.00292
15. Zhang LP, Yin JX, Liu Z, Zhang Y, Wang QS, Zhao J (2006) Effect of resveratrol on L-type calcium current in rat ventricular myocytes. Acta Pharmacol Sin 27:179–183. doi:10.1111/j.1745-7254.2006.00250.x
16. Park SJ, Ahmad F, Philp A, Baar K, Williams T, Luo H, Ke H, Rehmann H, Taussig R, Brown AL, Kim MK, Beaven MA, Burgin AB, Manganiello V, Chung JH (2012) Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 148:421–433. doi:10.1016/j.cell.2012.01.017
17. Price NL, Gomes AP, Ling AJ, Duarte FV, Martin-Montalvo A, North BJ, Agarwal B, Ye L, Ramadori G, Teodoro JS, Hubbard BP, Varela AT, Davis JG, Varamini B, Hafner A, Moaddel R, Rolo AP, Coppari R, Palmeira CM, de Cabo R, Baur JA, Sinclair DA (2012) SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab 15:675–690. doi:10.1016/j.cmet.2012.04.003
18. Higashida K, Kim SH, Jung SR, Asaka M, Holloszy JO, Han DH (2013) Effects of resveratrol and SIRT1 on PGC-1alpha activity and mitochondrial biogenesis: a reevaluation. PLoS Biol 11:e1001603. doi:10.1371/journal.pbio.1001603
19. Xia N, Strand S, Schlufter F, Siuda D, Reifenberg G, Kleinert H, Forstermann U, Li H (2013) Role of SIRT1 and FOXO factors in eNOS transcriptional activation by resveratrol. Nitric Oxide 32:29–35. doi:10.1016/j.niox.2013.04.001
20. Wen D, Huang X, Zhang M, Zhang L, Chen J, Gu Y, Hao CM (2013) Resveratrol attenuates diabetic nephropathy via modulating angiogenesis. PLoS One 8:e82336. doi:10.1371/journal.pone.0082336
21. Xu F, Wang Y, Cui W, Yuan H, Sun J, Wu M, Guo Q, Kong L, Wu H, Miao L (2014) Resveratrol Prevention of Diabetic Nephropathy Is Associated with the Suppression of Renal Inflammation and Mesangial Cell Proliferation: possible Roles of Akt/NF-kappaB Pathway. Int J Endocrinol 2014:289327. doi:10.1155/2014/289327
22. Gordish KL, Beierwaltes WH (2014) Resveratrol induces acute endothelium-dependent renal vasodilation mediated through nitric oxide and reactive oxygen species scavenging. Am J Physiol Renal Physiol 306:F542–F550. doi:10.1152/ajprenal.00437.2013
23. Um JH, Park SJ, Kang H, Yang S, Foretz M, McBurney MW, Kim MK, Viollet B, Chung JH (2010) AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 59:554–563. doi:10.2337/db09-0482
24. Pan Y, Wang Y, Cai L, Cai Y, Hu J, Yu C, Li J, Feng Z, Yang S, Li X, Liang G (2012) Inhibition of high glucose-induced inflammatory response and macrophage infiltration by a novel curcumin derivative prevents renal injury in diabetic rats. Br J Pharmacol 166:1169–1182. doi:10.1111/j.1476-5381.2012.01854.x
25. Pan Y, Zhu G, Wang Y, Cai L, Cai Y, Hu J, Li Y, Yan Y, Wang Z, Li X, Wei T, Liang G (2013) Attenuation of high-glucose-induced inflammatory response by a novel curcumin derivative B06 contributes to its protection from diabetic pathogenic changes in rat kidney and heart. J Nutr Biochem 24:146–155. doi:10.1016/j.jnutbio.2012.03.012
26. Zarkovic N (2003) 4-hydroxynonenal as a bioactive marker of pathophysiological processes. Mol Aspects Med 24:281–291
27. Mehlem A, Hagberg CE, Muhl L, Eriksson U, Falkevall A (2013) Imaging of neutral lipids by oil red O for analyzing the metabolic status in health and disease. Nat Protoc 8:1149–1154. doi:10.1038/nprot.2013.055
28. Kim J, Ahn JH, Kim JH, Yu YS, Kim HS, Ha J, Shinn SH, Oh YS (2007) Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway. Exp Eye Res 84:886–893. doi:10.1016/j.exer.2007.01.009
29. Wu XP, Xiong M, Xu CS, Duan LN, Dong YQ, Luo Y, Niu TH, Lu CR (2015) Resveratrol induces apoptosis of human chronic myelogenous leukemia cells in vitro through p38 and JNK-regulated H2AX phosphorylation. Acta Pharmacol Sin 36:353–361. doi:10.1038/aps.2014.132
30. Li J, Qu X, Ricardo SD, Bertram JF, Nikolic-Paterson DJ (2010) Resveratrol inhibits renal fibrosis in the obstructed kidney: potential role in deacetylation of Smad3. Am J Pathol 177:1065–1071. doi:10.2353/ajpath.2010.090923
31. Palsamy P, Subramanian S (2011) Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2-Keap1 signaling. Biochim Biophys Acta 1812:719–731. doi:10.1016/j.bbadis.2011.03.008
32. Fan H, Yang HC, You L, Wang YY, He WJ, Hao CM (2013) The histone deacetylase, SIRT1, contributes to the resistance of young mice to ischemia/reperfusion-induced acute kidney injury. Kidney Int 83:404–413. doi:10.1038/ki.2012.394
33. Jia Y, Kim S, Kim J, Kim B, Wu C, Lee JH, Jun HJ, Kim N, Lee D, Lee SJ (2015) Ursolic acid improves lipid and glucose metabolism in high-fat-fed C57BL/6J mice by activating peroxisome proliferator-activated receptor alpha and hepatic autophagy. Mol Nutr Food Res 59:344–354. doi:10.1002/mnfr.201400399
34. Grygiel-Gorniak B (2014) Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications–a review. Nutr J 13:17. doi:10.1186/1475-2891-13-17
35. Calleri E, Pochetti G, Dossou KS, Laghezza A, Montanari R, Capelli D, Prada E, Loiodice F, Massolini G, Bernier M, Moaddel R (2014) Resveratrol and its metabolites bind to PPARs. ChemBioChem 15:1154–1160. doi:10.1002/cbic.201300754
36. Inoue H, Jiang XF, Katayama T, Osada S, Umesono K, Namura S (2003) Brain protection by resveratrol and fenofibrate against stroke requires peroxisome proliferator-activated receptor alpha in mice. Neurosci Lett 352:203–206